Author

Weiliang Du

Observed names: W. Du, Weliang Du

Institution: The University of Texas MD Anderson Cancer Center

Observed institution: The University of Texas MD Anderson Cancer Center

ORCID: 0000-0001-6644-9802

Observed ORCID: 0000-0001-6644-9802

OpenAlex ID: A5024744978

INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806.

2020 · Parminder Singh, Cathy Tangen, et al. · Journal of Clinical Oncology · 23

Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial

2025 · Comron Hassanzadeh, Deborah Kuban, et al. · Journal of Clinical Oncology · 2

Identifying a Subgroup of High-Risk Prostate Cancer Patients With Worse Clinical Outcomes: Should There Be a “Very High-Risk” Group?

2016 · S. Choi, L.B. Levy, et al. · International Journal of Radiation Oncology*Biology*Physics

Works count: 3

Citation count: 25

H-index: 2

I10-index: 1